Cutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis

Cutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis

AimCutaneous adverse events (CAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized. To determine the association of BRAF and MEK inhibitor treatment with CAEs in patients with melanoma compared with BRAF inhibitor alone.MethodPubMed, Cochrane,...

Full description

Saved in:

Bibliographic Details
Main Authors:	Junhui Qian, Jinlong Wan, Qin Yao, Yin Chen, Tao Ling, Yuejuan Zhang, Zhihua Tang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Pharmacology
Subjects:	cutaneous adverse events BRAF inhibitor mek inhibitor melanoma meta analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1457226/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis
by: Jianhao Bai, et al.
Published: (2025-01-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
by: Malte Beckmann, et al.
Published: (2024-11-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review
by: Nina Yu, et al.
Published: (2024-12-01)

Spontaneous haematoma: A unique immune-related adverse event alongside other cutaneous reactions in a patient treated with pembrolizumab for metastatic melanoma
by: Dalila Malek, et al.
Published: (2024-12-01)

Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol‐3‐kinase inhibitors: A systematic review and meta‐analysis of randomized controlled trials
by: Yushu Wang, et al.
Published: (2023-02-01)

Practical application of precision oncology in adult onset craniopharyngiomas
by: Chandrima Biswas, et al.
Published: (2024-11-01)

Cutaneous adverse events due to checkpoint inhibitors – a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022
by: Clara Furrer-Matcau, et al.
Published: (2024-12-01)

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01)

Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim–Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report
by: Yuto Hibino, et al.
Published: (2024-12-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
by: Natalie Bourand, MS, et al.
Published: (2025-02-01)

Defining the high-risk category of patients with cutaneous melanoma: a practical tool based on prognostic modeling
by: Oleksandr Dudin, et al.
Published: (2025-02-01)

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
by: Camille M. Powers, et al.
Published: (2024-12-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
by: Yu. S. Shakh-Paronyants, et al.
Published: (2023-03-01)

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital
by: Gloria Juan-Carpena, et al.
Published: (2025-01-01)

A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database
by: Ya-Jun Zhang, et al.
Published: (2024-12-01)

Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events
by: Li Chen, et al.
Published: (2025-01-01)

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01)

Topical ruxolitinib for treatment-induced vitiligo in a patient with metastatic melanoma
by: Alpaslan Tasdogan, MD, PhD, et al.
Published: (2025-01-01)

Melanoma genomics – will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2024-09-01)

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
by: Alisa Lepper, et al.
Published: (2023-12-01)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
by: Yuan Meng, et al.
Published: (2024-07-01)

Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis
by: Teng Y, et al.
Published: (2024-11-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer
by: Tobias Max Philipp Hartwich, et al.
Published: (2024-09-01)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
by: A Daban, et al.
Published: (2023-12-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

Braf-Mutant Melanomas: Biology and Therapy
by: Elvira Pelosi, et al.
Published: (2024-12-01)

Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01)

TNF-α inhibitors as therapy for drug-induced severe cutaneous adverse reactions: a case series
by: Yanjun Chu, et al.
Published: (2024-12-01)

BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center’s experience
by: S. S. McThenia, et al.
Published: (2025-01-01)

Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis
by: Yana Yang, et al.
Published: (2024-11-01)

Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells
by: Ceyda Colakoglu Bergel, et al.
Published: (2025-01-01)

Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
by: Josué Ballesteros-Álvarez, et al.
Published: (2024-10-01)

Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01)

Synergistic ROS Reduction Through the Co-Inhibition of BRAF and p38 MAPK Ameliorates Senescence
by: Myeong Uk Kuk, et al.
Published: (2024-11-01)

Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors
by: Qi Zhang, et al.
Published: (2024-12-01)

RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION
by: Bello Abdullahi Umar, et al.
Published: (2019-12-01)